C12N7/08

Method of attenuating porcine pseudorabies virus, attenuated strains of porcine pseudorabies virus, vaccine composition and use thereof

This invention provides a method of attenuating porcine pseudorabies virus, which can effectively and reproducibly attenuate porcine pseudorabies virus. The attenuated strain of porcine pseudorabies virus by use of said method can provide effective immunization for pigs.

Method of attenuating porcine pseudorabies virus, attenuated strains of porcine pseudorabies virus, vaccine composition and use thereof

This invention provides a method of attenuating porcine pseudorabies virus, which can effectively and reproducibly attenuate porcine pseudorabies virus. The attenuated strain of porcine pseudorabies virus by use of said method can provide effective immunization for pigs.

Live-Attenuated Yellow Fever Virus Strain Adapted to Grow on Vero Cells and Vaccine Composition Comprising the Same

The invention relates to a live-attenuated yellow fever virus strain adapted to grow on Vero cells from a parent yellow fever virus 17D substrain that is not adapted to grow on Vero cells, wherein said live-attenuated yellow fever virus strain is less neurovirulent than said parent yellow fever virus 17D substrain.

Live-attenuated yellow fever virus strain adapted to grow on Vero cells and vaccine composition comprising the same

The invention relates to a live-attenuated yellow fever virus strain adapted to grow on Vero cells from a parent yellow fever virus 17D substrain that is not adapted to grow on Vero cells, wherein said live-attenuated yellow fever virus strain is less neurovirulent than said parent yellow fever virus 17D substrain.

SYSTEM AND METHOD TO DETERMINE CRITICAL PROCESS PARAMETERS FOR A CONTINUOUS VIRAL INACTIVATION REACTOR TO DESIGN AND MANUFACTURE SAME
20210388323 · 2021-12-16 ·

A viral inactivation device including at least one experimental continuous viral inactivation reactor having at least an inlet, an outlet, and a tubular flow path and a computer system that, based on the experimental continuous viral inactivation reactor can design, select, make, and/or manufacture a scaled actual reactor. The tubular flow path includes a set of alternating turns that form a serpentine or an interwoven pattern between the inlet and the outlet.

SYSTEM AND METHOD TO DETERMINE CRITICAL PROCESS PARAMETERS FOR A CONTINUOUS VIRAL INACTIVATION REACTOR TO DESIGN AND MANUFACTURE SAME
20210388323 · 2021-12-16 ·

A viral inactivation device including at least one experimental continuous viral inactivation reactor having at least an inlet, an outlet, and a tubular flow path and a computer system that, based on the experimental continuous viral inactivation reactor can design, select, make, and/or manufacture a scaled actual reactor. The tubular flow path includes a set of alternating turns that form a serpentine or an interwoven pattern between the inlet and the outlet.

Live-attenuated yellow fever virus strain adapted to grow on Vero cells and vaccine composition comprising the same

The invention relates to a live-attenuated yellow fever virus strain adapted to grow on Vero cells from a parent yellow fever virus 17D substrain that is not adapted to grow on Vero cells, wherein said live-attenuated yellow fever virus strain is less neurovirulent than said parent yellow fever virus 17D substrain.

Live-Attenuated Yellow Fever Virus Strain Adapted to Grow on Vero Cells and Vaccine Composition Comprising the Same

The invention relates to a live-attenuated yellow fever virus strain adapted to grow on Vero cells from a parent yellow fever virus 17D substrain that is not adapted to grow on Vero cells, wherein said live-attenuated yellow fever virus strain is less neurovirulent than said parent yellow fever virus 17D substrain.

Canine Parvovirus
20230405110 · 2023-12-21 · ·

The invention relates to a live attenuated parvovirus for use in the protection of an animal against parvovirus infection, wherein the live attenuated parvovirus is administered to the animal as a single dose and is administered during weeks 2-10 of age of the animal. The invention further relates to vaccines comprising the live attenuated parvovirus as well as methods for their production.

Canine Parvovirus
20230405110 · 2023-12-21 · ·

The invention relates to a live attenuated parvovirus for use in the protection of an animal against parvovirus infection, wherein the live attenuated parvovirus is administered to the animal as a single dose and is administered during weeks 2-10 of age of the animal. The invention further relates to vaccines comprising the live attenuated parvovirus as well as methods for their production.